Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT-04: Sacituzumab govitecan + pembrolizumab vs physician's choice chemotherapy + pembrolizumab in first-line PD-L1+ metastatic TNBC
jRCT2041220123Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) and breast cancer comparing Sacituzumab govitecan + pembrolizumab with Physician's choice chemotherapy + pembrolizumab (2 arms). Primary endpoint: Progression-free survival by BICR per RECIST v1.1. Started Feb 2023; status: active, not recruiting.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on jRCT2041220123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220123.